EMA Application withdrawn: Amtagvi (lifileucel) — Iovance Biotherapeutics B.V.

View source ↗

Summary

EMA has withdrawn the application for Amtagvi (lifileucel) for melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Amtagvi (lifileucel)

Snippet

Status: Application withdrawn. Therapeutic area: Melanoma. MAH: Iovance Biotherapeutics B.V.